Health Blueprint

Back to Longevity News

News summary

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

Source: PR Newswire • Published: 31 Oct 2026, 05:00

Summarized by Masters of Longevity from PR Newswire.

Zhimeng enrolled 255 patients in a pivotal Phase 2/3 ALS trial in China.

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
Key Takeaways
  • The trial enrolled 255 ALS patients across 15 Chinese centers.
  • The primary endpoint is change in ALSFRS-R score at Week 39.
  • Positive Phase 2 topline results may prompt conditional approval.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.